1 citations · 1 across the 2 of their papers we have counts for
2 papers
stat.ME2023★ 1 cited
Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization
Peng Yang, Daniel Li, Ruitao Lin +2
The conventional more-is-better dose selection paradigm, which targets the maximum tolerated dose (MTD), is not suitable for the development of targeted therapies and immunotherapi…
stat.ME2021
BOP2-DC: Bayesian optimal phase II designs with dual-criterion decision making
Yujie Zhao, Daniel Li, Rong Liu +1
The conventional phase II trial design paradigm is to make the go/no-go decision based on the hypothesis testing framework. Statistical significance itself alone, however, may not…